Havelaar I J, Sugarbaker P H, Vermess M, Miller D L
Cancer. 1984 Jul 1;54(1):163-71. doi: 10.1002/1097-0142(19840701)54:1<163::aid-cncr2820540131>3.0.co;2-v.
Monitoring the progression or regression of intraabdominal metastatic disease is required for knowledgeable management of chemotherapeutic regimens designed to treat metastases. Computerized tomography (CT) and CT with EOE-13, a liver contrast agent, allowed precise measurement of metastatic disease. The tumor doubling time of colorectal metastases in four patients was determined from serial CT scans of individual patients. Tumor doubling times of untreated patients varied from 50 to 95 days, and were in the same range for hepatic, lymph node, or intraperitoneal metastatic disease. These data may indicate that metastatic disease of colorectal cancer progresses at a faster rate in the peritoneal cavity than is reported for colorectal cancer metastatic to the lungs. The response to chemotherapy or progression of disease was also determined in treated patients. High resolution CT scanning with EOE-13 allowed calculation of tumor doubling times, and therefore more precise management of cancer patients with metastases.
为了对旨在治疗转移灶的化疗方案进行明智的管理，需要监测腹内转移性疾病的进展或消退情况。计算机断层扫描（CT）以及使用肝脏造影剂EOE - 13的CT能够精确测量转移性疾病。通过对4例患者进行连续的CT扫描，确定了结直肠转移瘤的肿瘤倍增时间。未治疗患者的肿瘤倍增时间在50至95天之间，肝、淋巴结或腹膜内转移性疾病的肿瘤倍增时间也在同一范围内。这些数据可能表明，结直肠癌的转移性疾病在腹膜腔中的进展速度比报道的结直肠癌肺转移更快。还对接受治疗的患者确定了化疗反应或疾病进展情况。使用EOE - 13的高分辨率CT扫描能够计算肿瘤倍增时间，从而对有转移灶的癌症患者进行更精确的管理。
